Ignite Creation Date:
2025-12-25 @ 1:20 AM
Ignite Modification Date:
2026-03-05 @ 3:58 PM
Study NCT ID:
NCT00472693
Status:
COMPLETED
Last Update Posted:
2020-04-09
First Post:
2007-05-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
UPCC 02106
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |